iBio, Inc. - 8-K Filing

iBio reports extended preclinical data for IBIO-610 showing 2.3% body weight reduction in NHPs and amylin program selectivity. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IBIO

Read the full article at SEC EDGAR

Part of the story CG Oncology, Inc. - 8-K Filing (3 articles)

More Regulatory news